Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

9-1-2019

Apixaban Concentrations with Lower than Recommended Dosing
in Older Adults with Atrial Fibrillation
Smrithi Sukumar
UCSF School of Medicine

Markus Gulilat
Schulich School of Medicine & Dentistry

Bradley Linton
London Health Sciences Centre

Steven E. Gryn
Schulich School of Medicine & Dentistry

George K. Dresser
Schulich School of Medicine & Dentistry

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Sukumar, Smrithi; Gulilat, Markus; Linton, Bradley; Gryn, Steven E.; Dresser, George K.; Alfonsi, Jeffrey E.;
Schwarz, Ute I.; and Kim, Richard B., "Apixaban Concentrations with Lower than Recommended Dosing in
Older Adults with Atrial Fibrillation" (2019). Paediatrics Publications. 1565.
https://ir.lib.uwo.ca/paedpub/1565

Authors
Smrithi Sukumar, Markus Gulilat, Bradley Linton, Steven E. Gryn, George K. Dresser, Jeffrey E. Alfonsi, Ute
I. Schwarz, and Richard B. Kim

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/1565

UCSF
UC San Francisco Previously Published Works
Title
Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial
Fibrillation.

Permalink
https://escholarship.org/uc/item/3w8526cp

Journal
Journal of the American Geriatrics Society, 67(9)

ISSN
0002-8614

Authors
Sukumar, Smrithi
Gulilat, Markus
Linton, Bradley
et al.

Publication Date
2019-09-01

DOI
10.1111/jgs.15982
Peer reviewed

eScholarship.org

Powered by the California Digital Library
University of California

1
1 Apixaban concentrations with lower than recommended dosing in older adults with

atrial fibrillation

2
3
4
5Smrithi Sukumar

Markus Gulilat, PhD b , Bradley Linton

a,

c,

Steven E. Gryn, MDb ,

6George K. Dresser, MD b , Jeffrey E. Alfonsi, MD b , Ute I. Schwarz, MD, PhD b ,
7Richard B. Kim, MD b, Janice B. Schwartz, MD

a

8a University of California, San Francisco, San Francisco, CA
9bSchulich School of Medicine and Dentistry, Western University, London, ON
10Canada
11
12cPharmacy Services, London Health Sciences Centre, London, ON Canada
13
14Corresponding Author:

Janice B. Schwartz, MD

15

3333 California Street, UCSF Box 1265

16

San Francisco, CA 94143-1265

17

Email: Janice.schwartz@ucsf.edu

18Alternate corresponding author:
19

Smrithi Sukumar

Email Smrithi.Sukumar@ucsf.edu

20Manuscript Word Count:
21Abstract Word Count:

phone: (415)502-3710

2010

Figures: 2

Tables: 1

298

22Smrithi Sukumar was supported in part by T35 AG026736 Medical Student
23Training in Aging Research (MSTAR) Program. This work was supported by the
24Wolfe Medical Research Chair in Pharmacogenomics (Richard B. Kim), the
25Canadian Institutes of Health Research (DSEN-PREVENT, FRN-117588 (Richard B.
26Kim)), and Ontario Research Fund-Research Excellence Grant (Richard B. Kim).

2
27Selected for Presidential Poster Session at for AGS 2019 meeting
28Running title:
29
30
31

Apixaban levels in older NVAF patients
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32ABSTRACT
33
34Background/ Objectives
35Lower-than-recommended doses of direct-acting oral anticoagulants are often
36prescribed to older adults with non-valvular atrial fibrillation (NVAF). Our goal was
37to determine the consequences of lower-than- recommended dosing on plasma
38apixaban concentrations during clinical care of older adults with NVAF.
39Design
40Convenience sample of patients receiving anticoagulation during 2017
41Setting
42Academic medical center
43Participants
44Stable adults over age 65 years with non-valvular atrial fibrillation receiving
45apixaban on a chronic basis
46Measurements
47Patient age, weight, creatinine, co-medications, apixaban concentrations
48Results
49One hundred and ten older adults with NVAF (mean age of 80.4 years, range 6650100 with 45% women) were studied. Forty-eight patients received recommended
51dosing of 5 mg twice daily and 42 received lower-than-recommended dosing. One
52patient in each category had concentrations below expected 5-95% range at time
53of peak concentrations. Differences in proportion of apixaban concentrations within
54or outside expected ranges were not significant between patients receiving lower55than-recommended doses and those dosed-as-recommended at 5 mg twice daily

4
56(p=0.35). However, in patients dosed-as-recommended with 5 mg twice daily, four
57had concentrations above 5-95% range for peak levels expected at 3-4 hours after
58dosing; in two, this occurred around the midpoint of the dosing interval. Twenty
59patients received 2.5 mg twice daily as recommended. One third had apixaban
60concentrations higher than expected peak concentrations compared to the clinical
61trials and, over 2/3 had levels above the reported median for peak concentrations.
62Conclusions
63Apixaban concentrations in older adults with NVAF seen clinically were higher than
64expected based on clinical trial data. The findings raise questions about the
65optimal dosing of apixaban in older adults with NVAF encountered outside of
66clinical trials and suggest a role for monitoring of apixaban concentrations during
67care of patients that differ from those in randomized trials, or when considering
68dosing outside of published guidelines.
69
70Keywords: apixaban, direct-acting oral anticoagulant, non-valvular atrial fibrillation,
71dosing accuracy,
72
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73INTRODUCTION
74Direct-acting oral anticoagulants (DOACs) are replacing vitamin K antagonists for
75anticoagulation due to fewer food and medication interactions and simplified dosing and
76monitoring regimens.

1

While DOACs have been shown to have equivalent or superior

77efficacy to prevent stroke or systemic emboli in patients with non-valvular atrial fibrillation
78(NVAF) with fewer intracranial hemorrhages in randomized trials, 2-4 there are limited data
79on older adults with NVAF during routine clinical care. These patients are often older,
80more likely to be women, have more co-morbidities, falls, and higher bleeding risks than
81those enrolled in clinical trials. Possibly due to these factors, post-marketing analyses
82of DOAC use in patients with NVAF report prescribed doses often inconsistent with
83product labelling.

1

Lower-than-recommended dosing is more common than higher-

84than-recommended dosing, especially for apixaban in older patients.5,6

7,8

85The consequences of under-dosing are currently uncertain. If under-dosing resulted in
86lower apixaban concentrations, increased stroke rates would be expected, as would lower
87bleeding rates. Analyses from administrative claims data lacking full assessment of
88dosing accuracy reported increased stroke rates without increased bleeding in patients
89with NVAF receiving apixaban classified as “under-dosed”.

7

Under-dosing was also

90initially reported to result in worse outcomes in patients enrolled in The Outcomes
91Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF) registry.

9

92However, when the outcomes were adjusted for patient risk characteristics, no significant
93difference in outcomes between “under-dosed” patients compared to patients dosed as
94recommended was detected in the ORBIT-AF registry.

10

These studies did not determine

95drug concentrations in relation to dosing or outcomes to investigate potential mechanisms
96for alterations in responses or outcomes.

6
97Our primary goal was to measure plasma apixaban concentrations during routine
98clinical care of older adults with NVAF and compare apixaban concentrations
99between patients receiving recommended vs. lower-than-recommended dosing
100relative to concentrations reported from the pivotal trial on which marketing
101approval was granted (ARISTOTLE trial).

11

We found that older adults with NVAF

102receiving lower than recommended dosing of apixaban had the same proportion of
103concentrations within the ranges reported from patients receiving recommended doses,
104and, only patients receiving recommended doses had concentrations in excess of those
105observed in clinical trials.
106METHODS
107 Patients and Data Collection. Clinically stable older adults with NVAF taking
108apixaban and seen at least once at an anticoagulation clinic during 2017 were
109invited to participate in the study. Written informed consent was obtained per
110protocol approved by the Health Sciences Research Ethics Board of the University
111of Western Ontario (London, Ontario, Canada). Patient age, sex, weight, height,
112apixaban dose regimen, concomitant use of moderate (amiodarone, diltiazem,
113fluconazole, verapamil) to strong (clarithromycin, ketoconazole, ritonavir) P114gp/CYP3A4 inhibitors and P-gp/CYP3A4 inducers (carbamazepine, phenytoin,
115phenobarbital, rifampin) , most recent serum creatinine, and date/time of last
116apixaban dose were collected when single steady-state blood samples were
117obtained. Blood samples were immediately stored at -4ºC before centrifugation at
1182000g for 10 minutes for plasma isolation. Plasma samples were stored at -80ºC
119until further analysis. Apixaban concentrations were determined by liquid

7
120chromatography tandem mass spectrometry as previously reported.

12

Lower limit

121of quantitation is 5 ng/mL. Assay performance across the 25, 250, and 1000
122ng/mL quality controls were 1.5% and 8.5%, intraday bias and precision was 1.3%
123and 5.1%.
124Data analysis. Dosing was categorized as recommended, higher-than, or lower125than-recommended. Recommended apixaban dosing in 5 mg twice daily reduced
126to 2.5 mg twice daily with two of the following present: age > 80 y, weight < 60
127kg, serum creatinine > 1.5 mg/dL, or a strong CYP3A4/P-gp inhibitor is co128administered without 2 of the 3 dose reduction criteria.
129(https://packageinserts.bms.com/pi/pi_eliquis.pdf). For patients meeting
130recommendations for 5 mg twice daily, apixaban concentrations were categorized
131as being within, higher, or lower than the expected 5-95% percentile at peak (91132321 ng/mL, median =171 ng/mL) or trough (41-230 ng/mL, median =103 ng/mL )
133compared to patients receiving 5 mg twice daily in the pivotal ARISTOTLE trial.

11

134For patients receiving 2.5 mg twice daily as recommended, concentrations were
135similarly categorized in reference to patients receiving 2.5 mg twice daily in
136ARISTOTLE ( peak: 69-221 ng/mL, 123 median; trough: 34-162 ng/mL, median 79
137ng/mL). Concentrations were analyzed in relation to dosing accuracy by Chi Square
138RESULTS
139One hundred ten patients were studied (see Table 1 for characteristics). No
140patients received higher- than-recommended dosing. Sixty-eight patients received
141recommended dosing: 5 mg twice daily in 48 (26 had one dose reduction criteria:
142age in 16, weight in 3, creatinine in 7), and 2.5 mg twice daily in 20 (age criteria in

8
143all; creatinine criteria in 13, weight criteria in 9 (two patients met all 3 dose
144reduction criteria). Forty-two received lower-than-recommended dosing of 2.5 mg
145twice daily (29 had one dose reduction criteria: age in 21, weight in 2, creatinine in
1466). No patients received strong CYP3A4/5 P-gP inhibitors.
147
148Apixaban concentrations after dosing in patients receiving the recommended dose
149of 5 mg twice daily and those receiving lower than recommended dosing at 2.5 mg
150twice daily are shown in Figure 1. One dosed as recommended and one dosed
151lower than recommended patient had concentrations below the expected 5-95%
152range at expected time of peak concentrations (91-321 ng/ml). In patients dosed153as-recommended with 5 mg twice daily, four (two older than age 90) had
154concentrations above expected 5-95% range at peak that occurred later than the
155reported 3-4 hours after dosing time of peak concentrations in two. Few patients
156were sampled at trough (12 hours after dosing) but none had concentrations below
157expected 5-95% range at trough in either group. No significant differences in
158proportion of apixaban concentrations within or outside expected ranges were
159detected between patients receiving lower-than-recommended doses and those
160dosed as recommended (p=0.35).
161Concentrations from patients receiving appropriately reduced doses were
162compared to data from ARISTOTLE participants receiving appropriately reduced
163doses. Concentration vs. time data for these twenty patients receiving 2.5 mg
164twice daily as recommended are shown in Figure 2. Concentrations above the 516595% range for expected peak from ARISTOTLE data (69-221 ng/mL) were seen in 7

9
166of the 20 as late as 7 hours after dosing.

Seventeen of the twenty had

167concentrations from 3 to 8.5 hours after dosing that were above the expected
168median peak level at 3-4 hours (123 ng/mL).
169
170DISCUSSION
171
172Our goal was to determine apixaban concentrations in older and very old adults in
173the community being treated with apixaban for the prevention of stroke in the
174presence of non-valvular atrial fibrillation. The mean age of patients studied in this
175report is 80.4 years (range 66-100), women represented 45% of the group, and
176one third received lower than recommended dosing.

There are several key

177observations from our study. One is that patients receiving reduced dosages
178without meeting criteria for dosage reduction had apixaban concentrations within
179the ranges reported for the recommended doses. A second point is that a low and
180similar proportion of concentrations below expected peak concentrations was seen
181in patients receiving 2.5 mg twice daily without meeting criteria for dose
182reductions compared to patients receiving the recommended 5 mg twice daily.
183Third, only patients receiving recommended 5 mg twice daily dosing had
184concentrations far in excess of the expected 5-95% range for peak concentrations
185Numbers were small and the trend was not significant but raises concern as
186increasing apixaban concentrations produce greater anticoagulation and older
187adults are at higher basal risk for bleeding. Fourth, patients receiving

10
188appropriately reduced doses of 2.5 mg twice daily had concentrations greater than
189patients receiving the 2.5 mg twice daily in the clinical trials. Finally, the data also
190suggest that clinicians recognize characteristics of patients that may warrant
191dosage reductions from recommendations based on randomized clinical trials.
192
193Current clinical dosing recommendations for DOACs reflect the regimens that were used
194in the efficacy trials on which marketing approval was granted. For apixaban,
195recommended standard dosing is 5 mg twice daily reduced to 2.5 mg twice daily if
196the patient has two of the following characteristics: 80 years or older, weight of 60
197kg or below, creatinine of 1.5 mg/dL or above; or, is co-administered a strong
198CYP3A4/5 P-gP inhibitor. (https://packageinserts.bms.com/pi/pi_eliquis.pdf). Dosing
199with 2.5 mg twice daily in the absence of 2 of the 3 criteria represents a 50%
200reduction from recommendations. The algorithm appears to have been selected to
201account qualitatively for possible changes in drug distribution or clearance
202(without more precise estimates of creatinine clearance) or the increased risk of
203bleeding in the very elderly.

Most pivotal pre-marketing trials of DOACs did not

204report measurement of concentrations or anticoagulant effects and thus
205prescribing guidelines do not advocate laboratory monitoring of either DOAC
206concentrations or effects. However, DOAC concentrations are directly related to
207factor Xa inhibition and anticoagulation. Data recently published from the earlier
208trials show dabigatran and edoxaban have a direct relationship between drug
209concentrations, factor Xa inhibition and efficacy as well as bleeding outcomes for
210the treatment of patients with NVAF.

13-15

Apixaban concentration data from NVAF

11
211clinical trials have recently been analyzed and published but have not been related
212to clinical outcomes.

16,17

Clinical laboratories are establishing DOAC assays and

213report the concentration
214data from the clinical trials as reference ranges.
215Importantly, pivotal non-valvular atrial fibrillation trials enrolled patients with mean
216age of 70 years, fewer women than men, almost no racial minorities, no patients
217on dialysis, resulting in only about 5% receiving the reduced dose.

18

This leaves a

218critical deficiency of data on use of apixaban in the complex and heterogeneous
219population of older adults with NVAF. Post-marketing registry studies or analyses
220of claims data have attempted to address this gap, and in general report equal
221efficacy in clinical populations to that seen during clinical trials.

7,9,10,19-22

However,

222major extracranial and GI bleeding rates were similar for warfarin and DOACs in
223NVAF trials. Rates for major bleeding of 2.6-3.3% were reported for patients over
224age 75y in ARISTOTLE and were 4.5% per year for major and clinically relevant
225nonmajor bleeding in patients unsuitable for warfarin in AVERROES.

2,23,24

Major

226bleeding rates reported from administrative claims data are on the order of 4% -5%
227per year for major bleeding

7,10 7 10,25

but range from 2.6 -10%.

7,10,26,27 28

No post-

228marketing studies have analyzed either drug concentrations or factor Xa inhibition
229in relation to dosing or outcomes.

When doses are higher than recommended,

230major bleeding rates rise 7and have been reported as 6.9% 9. We recognize our
231data are preliminary. Our sample was not random and patients receiving 2.5 mg
232twice daily not meeting dose reduction criteria were likely oversampled. Patients
233were seen or followed in a specialized anticoagulation clinic at a tertiary care

12
234medical center capable of monitoring apixaban concentrations as part of a
235research program. We did not have outcomes data to relate the concentrations to
236either efficacy or adverse bleeding events but used the surrogate marker of drug
237concentration ranges reported from the clinical trials as the reference range by
238clinical laboratories that perform DOAC assaysWe also did not have information on
239reasons physicians prescribed lower than recommended dosing. Nonetheless, the
240data suggest that concentration responses to doses of apixaban in older patients
241encountered during routine clinical care may differ from the somewhat limited data
242reported from clinical trials.
243There is a need for more information about prescribing, outcomes, as well as risks
244and benefits of DOAC use in the older patients with NVAF.

Until such data are

29

245available, the clinician is faced with balancing the high risk of embolic stroke from
246NVAF with the high risk of bleeding. Clinical laboratories are establishing DOAC
247assays and laboratory monitoring may provide helpful information.
248
249CONCLUSION
250Our findings raise questions about optimal dosing of apixaban in older adults with
251NVAF outside of clinical trials. Drug concentrations were higher than expected
252based on clinical trial data and should caution those who advocate that lower than
253recommended dosing be a target for correction. 30 Clinical laboratories are
254establishing DOAC assays and report the concentration data from the clinical trials
255as reference ranges. Our data support a role for monitoring factor Xa inhibition or

13
256apixaban concentrations when treating patients that differ from those in
257randomized trials, or when considering dosing outside of published guidelines.
258
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407
408
409LEGENDS
410Figure 1. Apixaban concentrations after dosing in patients with recommended
411

dosing of 5 mg twice daily.

412Apixaban concentrations after dosing are shown from patients receiving lower than
413recommended dosing of 2.5 mg twice daily in red and those receiving
414recommended dosing of 5 mg twice daily in green. Dashed vertical lines indicate
415expected 5-95% range (and median) at peak (91-321 ng/mL at 3-4hrs after dosing,
416median 171 ng/ml ) and trough (41-230 ng/mL, median 103 ng/mL at 12hrs after
417dosing).
418
419Figure 2. Apixaban concentrations after dosing in patients receiving
420recommended 2.4 mg twice daily.
421Apixaban concentrations after dosing are shown from patients receiving
422recommended dosing of 2.5 mg twice daily Dashed vertical lines indicate expected
4235-95% range (and median) at peak (69-221 ng/mL, median;123 ng/mL at 3-4hrs
424after dosing) and trough (34-162 ng/mL, median 79 ng/mL at 12hrs after dosing).
425

25
426Table 1. Patient Characteristics and Apixaban Dosing

Dosed as
Recommended
2.5 mg
twice daily
20

Dosed lower
than
Recommended
5 mg twice 2.5 mg twice
daily
daily
48
42

N

110

Age (y)
(range)

80.4± 7.8* 88.6 ±5.3
(66-100)
(80-100)

77.8 ±7.2
(66-96)

79.4 ±6.9
(67-96)

Sex (men,
women)
Race

60, 50

5, 15

33, 15

22, 20

White

White

White

White

Weight (kg)

86.4
±21.4
(44-140.3)

71.1±22.2
(45.8123.1)

94.6
±19.7
(58-140.3)

83.9±18.6
(44-118.4)

Creatinine
(mg/dL)

1.2±0.5
(0.6-2.7)

1.6 ±0.4
(0.8-2.7)

1.1 ±0.3
(0.6-2.0)

1.2±0.5
(0.6-2.7)

Creatinine
Clearance
(ml/min)

59 ± 27
14-143)

31 ± 15
(14-77)

68 ± 26
(35-143)

62 ± 24
(18-121)

Strong CYP3A4/5
P-gP Inhibitors
Moderate
CYP3A4/5 P-gP
Inhibitors^
Amiodarone
Diltiazem
Strong Inducer
(carbamazepine)

0

0

0

0

20

6

6

8

7
13
1

3
3
0

1
5
0

3
5
1

427
428*Data are mean ± SD, (range). ^ No dose adjustment recommended for moderate
429inhibitors.
430

26

431
432Figure 1.

433
434Figure 2.

